Clovis Oncology


Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 1.93 (2.49%)
Intraday High$79.60
Intraday Low$75.33
Data as of 10/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
10/23/17Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 23, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2017 financial results on Wednesday, November 1, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly Version 
10/09/17Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Filing based on positive phase 3 ARIEL3 clinical trial in which rucaparib significantly improved PFS in all ovarian cancer patient populations studied Company plans to file Marketing Authorization Application in Europe in early 2018 for maintenance treatment indication BOULDER, Colo.--(BUSINESS WIRE)--Oct. 9, 2017-- Clovis Oncology (NASDAQ: CLVS) announced today that the company has submitted a supplemental New ... 
Printer Friendly VersionDownload PDF
09/13/17Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet
ARIEL3 evaluated rucaparib as maintenance treatment among women with advanced ovarian cancer Study successfully achieved primary, key secondary and exploratory endpoints Company plans to submit a supplemental New Drug Application (sNDA) in the U.S. for maintenance treatment indication in ovarian cancer by the end of October 2017 BOULDER, Colo.--(BUSINESS WIRE)--Sep. 13, 2017-- Clovis O... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.